<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03593447</url>
  </required_header>
  <id_info>
    <org_study_id>TGDAG-C-2</org_study_id>
    <nct_id>NCT03593447</nct_id>
  </id_info>
  <brief_title>To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients</brief_title>
  <official_title>A Multicenter, Randomized, Open-label, Dose-ranging, Phase II Study to Evaluate the Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in Treatment naïve Subjects With Chronic Hepatic C Virus Genotype I Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II study to evaluate the efficacy and safety in TG-2349 combination with DAG181 (±&#xD;
      Ribavirin) in treatment naïve subjects with chronic hepatic C virus genotype I infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this phase II study is to evaluate the efficacy and safety in TG-2349&#xD;
      combination with DAG181 (± Ribavirin) in treatment naïve subjects with chronic hepatic C&#xD;
      virus genotype I infection. Approximately 132 subjects will be enrolled in this study and&#xD;
      divided into six groups:&#xD;
&#xD;
      Group 1 to 4: Chronic hepatics C virus (HCV) genotype 1 infected, treatment naïve,&#xD;
      non-cirrhotic subjects.&#xD;
&#xD;
      Group 5 to 6: Chronic hepatics C virus (HCV) genotype 1 infected, treatment naïve, cirrhotic&#xD;
      subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Actual">February 17, 2020</completion_date>
  <primary_completion_date type="Actual">April 23, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of antiviral efficacy (HCV RNA &lt; lower limit of quantification, target detected or target not detected) at 12 weeks after the end of treatment</measure>
    <time_frame>12 weeks after the end of treatment</time_frame>
    <description>To evaluate the antiviral efficacy of two different doses of TG-2349 combination with two different doses of DAG181(± Ribavirin) as measure by the proportion of subjects achieving sustained viral response (defined as HCV RNA &lt; lower limit of quantification, target detected or target not detected) at 12 weeks after the end of treatment (SVR 12) in treatment naïve subjects with chronic hepatic C virus genotype I infection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving HCV RNA &lt; LLOQ, TD or TND after the end of treatment (SVR4, SVR8, and SVR24).</measure>
    <time_frame>24 weeks after the end of treatment</time_frame>
    <description>To evaluate the proportion of subjects achieving sustained viral response at 4, 8, and 24 weeks after the end of treatment (SVR4, SVR8, and SVR24).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving HCV RNA &lt; LLOQ, TD or TND during treatment</measure>
    <time_frame>up to 16 weeks</time_frame>
    <description>To evaluate the proportion of subjects achieving HCV RNA &lt; lower limit of quantification, target detected or target not detected (&lt; LLOQ, TD or TND) during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects achieving HCV RNA &lt; LLOQ, TND during treatment and after the end of treatment.</measure>
    <time_frame>up to 40 weeks</time_frame>
    <description>To evaluate the proportion of subjects achieving HCV RNA &lt; LLOQ, TND during treatment and after the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the average time of first HCV RNA &lt; LLOQ, TND showing during treatment and after the end of treatment.</measure>
    <time_frame>up to 40 weeks</time_frame>
    <description>To evaluate the average time of first HCV RNA &lt; LLOQ, TND showing during treatment and after the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change from baseline of circulating blood HCV RNA</measure>
    <time_frame>up to 40 weeks</time_frame>
    <description>To evaluate the change from baseline of circulating blood HCV RNA during treatment and after the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the proportion of subjects with virologic failure</measure>
    <time_frame>up to 16 weeks</time_frame>
    <description>To evaluate the proportion of subjects with virologic failure (including breakthrough, rebound, or non-response) during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the proportion of subjects with virologic relapse</measure>
    <time_frame>24 weeks after the end of treatment</time_frame>
    <description>To evaluate the proportion of subjects with virologic relapse after the end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For subjects receiving study drugs who do not achieve SVR, the proportion and changes of TG-2349 or DAG181 resistant virus</measure>
    <time_frame>24 weeks after the end of treatment</time_frame>
    <description>For subjects receiving study drugs who do not achieve SVR, the proportion and changes of TG-2349 or DAG181 resistant virus will be monitored.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 2 days</time_frame>
    <description>To evaluate the maximum drug concentration in the blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve [AUC]</measure>
    <time_frame>up to 2 days</time_frame>
    <description>To evaluate the drug quantity in the blood</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">133</enrollment>
  <condition>Chronic Hepatics C Virus (HCV) Genotype 1</condition>
  <condition>Non-Cirrhotic</condition>
  <condition>Cirrhosis</condition>
  <condition>Treatment naïve</condition>
  <arm_group>
    <arm_group_label>non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. low dose TG-2349+ low dose DAG181+Ribavirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. high dose TG-2349+ high dose DAG181+Ribavirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-cirrhotic subjects. low TG-2349+ low DAG181</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. low dose TG-2349+ low dose DAG181</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-cirrhotic subjects. high TG-2349+ high DAG181</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV genotype 1 infected, treatment naïve, non-cirrhotic subjects. high dose TG-2349+ high dose DAG181</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV genotype 1 infected, treatment naïve, cirrhotic subjects. high dose TG-2349+ high dose DAG181+Ribavirin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cirrhotic subjects. high TG-2349+ high DAG181</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCV genotype 1 infected, treatment naïve, cirrhotic subjects. high dose TG-2349+ high dose DAG181</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin</intervention_name>
    <description>Group1: TG-2349 200 mg + DAG181 100 mg + Ribavirin 1000 mg or 1200 mg</description>
    <arm_group_label>non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin</intervention_name>
    <description>Group2: TG-2349 400 mg + DAG181 200 mg + Ribavirin 1000 mg or 1200 mg</description>
    <arm_group_label>non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>non-cirrhotic subjects. low TG-2349+ low DAG181</intervention_name>
    <description>Group 3: TG-2349 200 mg + DAG181 100 mg</description>
    <arm_group_label>non-cirrhotic subjects. low TG-2349+ low DAG181</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>non-cirrhotic subjects. high TG-2349+ high DAG181</intervention_name>
    <description>Group 4: TG-2349 400 mg + DAG181 200 mg</description>
    <arm_group_label>non-cirrhotic subjects. high TG-2349+ high DAG181</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin</intervention_name>
    <description>Group 5: TG-2349 400 mg + DAG181 200 mg + Ribavirin 1000 mg or 1200 mg_</description>
    <arm_group_label>cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cirrhotic subjects. high TG-2349+ high DAG181</intervention_name>
    <description>Group6: TG-2349 400 mg + DAG181 200 mg</description>
    <arm_group_label>cirrhotic subjects. high TG-2349+ high DAG181</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Before starting the study, an informed consent form (ICF) approved by the&#xD;
             Institutional Review Board (IRB) is obtained from the subject or his/her legal&#xD;
             representative；&#xD;
&#xD;
          2. Male or female, and 18 to 45 years of age inclusive when signing ICF；&#xD;
&#xD;
          3. Body mass index (BMI) in the range of 18.0 to 35.0kg/m2 and body weight ≥ 40 kg at&#xD;
             Screening；&#xD;
&#xD;
          4. Presence of chronic hepatitis C (CHC) as documented below: (1)A positive anti-HCV&#xD;
             antibody test or positive HCV RNA or positive HCV genotyping test at least 6 months&#xD;
             prior to the Baseline/Day 1 visit or, (2) A liver biopsy or FibroTest performed prior&#xD;
             to the Baseline/Day 1 visit with evidence of chronic HCV infection, such as the&#xD;
             presence of fibrosis and/or inflammation；&#xD;
&#xD;
          5. Positive for anti-HCV antibody at Screening；&#xD;
&#xD;
          6. Presence of an HCV RNA level ≥ 1 x 104 IU/mL at Screening as determined by the Central&#xD;
             Laboratory；&#xD;
&#xD;
          7. Presence of genotype 1a, 1b, or 1a/1b combination HCV-infection at Screening as&#xD;
             determined by the Central Laboratory；&#xD;
&#xD;
          8. HCV treatment naïve defined as no prior therapy with any interferon (IFN), ribavirin&#xD;
             (RBV), or other approved or investigational HCV-specific agent；&#xD;
&#xD;
          9. Without (group 1 to 4) or with (group5 to 6) cirrhosis: (1) Without cirrhosis as&#xD;
             defined as any one of the following: (a) Liver biopsy without showing cirrhosis (e.g.,&#xD;
             Metavir score &lt; F4 or Ishak score &lt; 5) within one year prior to Screening or at&#xD;
             Screening. (b) FibroScan showing cirrhosis or results ≤ 12.5 kPa within six months&#xD;
             prior to Screening or at Screening. (2) With cirrhosis as defined as any one of the&#xD;
             following: (a) Liver biopsy showing cirrhosis (e.g., Metavir score = F4 or Ishak score&#xD;
             ≥ 5) within one year prior to Screening or at Screening. (b) FibroScan showing&#xD;
             cirrhosis or results &gt; 12.5 kPa within six months prior to Screening or at&#xD;
             Screening；NOTICE: If there is liver biopsy, liver biopsy results will supersede&#xD;
             non-invasive testing results and be considered definitive.&#xD;
&#xD;
         10. ECG without clinically significant abnormalities at Screening；&#xD;
&#xD;
         11. Subjects must have the following laboratory parameters at Screening: (1) ALT ≤ 10 ×&#xD;
             the upper limit of normal (ULN). (2) AST ≤ 10 × ULN. (3) Without cirrhosis: Total&#xD;
             bilirubin ≤ 1.5 × ULN except history of Gilbert's syndrome. If Gilbert's syndrome is&#xD;
             the proposed etiology, the total bilirubin must ≤ 2 × ULN. With cirrhosis: Total&#xD;
             bilirubin ≤ 2 × ULN. (4) Platelet count ≥ 90,000 cells/mm3. (5) Absolute neutrophil&#xD;
             count (ANC) ≥ 1,500 cells/mm3. (6) HbA1c ≤ 8.5%. (7) Creatinine clearance (CLcr) ≥ 50&#xD;
             mL /min, as calculated by the Cockcroft-Gault equation. (8) Hemoglobin ≥ 110 g/L for&#xD;
             female subjects; ≥ 120 g/L for male subjects. (9) Without cirrhosis Albumin ≥ 3.5&#xD;
             g/dL；With cirrhosis Albumin ≥30g/L. (10) Without cirrhosis INR ≤ 1.5 x ULN；With&#xD;
             cirrhosis INR ≤ 1.7 x ULN. (11) Alpha fetoprotein (AFP)&lt;100 ng/mL；20ng/mL≤AFP≤100ng/mL&#xD;
             need to take Liver Ultrasonic testing to exclude subjects with suspicious liver cancer&#xD;
             cells. (12) Anti-nuclear antibodies (ANA) ≤ 1:320；&#xD;
&#xD;
         12. A female subject is eligible to enter the study if it is confirmed that she is: (1) Of&#xD;
             non-childbearing potential (i.e., women who have had a hysterectomy, have both ovaries&#xD;
             removed or medically documented ovarian failure, or are postmenopausal - women &gt; 50&#xD;
             years of age with cessation (for ≥12 months) of previously occurring menses), or (2)&#xD;
             Of childbearing potential (Women ≤ 50 years of age with amenorrhea will be considered&#xD;
             to be of childbearing potential). These women must have a negative serum pregnancy&#xD;
             test at Screening and agree to consistently and correctly use an approved&#xD;
             contraceptive method (i.e. abstinence, vaginal ring, cervical cap, contraceptive&#xD;
             diaphragm, or intrauterine devices) from screening until at least 6 months after the&#xD;
             last dose of study drug(s)；&#xD;
&#xD;
         13. Male subjects must agree to consistently and correctly use an approved contraceptive&#xD;
             method (i.e. abstinence, condom, or spouses using contraceptive drugs, vaginal ring,&#xD;
             cervical cap, contraceptive diaphragm, or intrauterine devices) from screening until&#xD;
             at least 6 months after the last dose of study drug(s)；&#xD;
&#xD;
         14. Male subjects must agree to refrain from sperm donation from screening until at least&#xD;
             6 months after the last dose of study drug(s)；&#xD;
&#xD;
         15. Subject must be of generally good health, with the exception of chronic HCV infection,&#xD;
             as determined by Investigator；&#xD;
&#xD;
         16. Subject must be able to comply with the dosing instructions for study drug&#xD;
             administration and able to complete the study schedule of assessments, including all&#xD;
             required post-treatment visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Positive serological test for IgM anti-HAV or anti-HEV antibody at Screening；&#xD;
&#xD;
          2. Positive serological test for HBsAg at Screening；&#xD;
&#xD;
          3. Positive test for HIV-1 or HIV-2 at Screening；&#xD;
&#xD;
          4. Donation or loss of more than 400 mL blood within 3 months prior to Baseline/Day 1；&#xD;
&#xD;
          5. Clinically-relevant drug abuse within 12 months of signing the ICF. A positive drug&#xD;
             screen will exclude subjects unless it can be explained by a prescribed medication;&#xD;
             the diagnosis and prescription must be approved by Investigator；&#xD;
&#xD;
          6. Alcohol misuse as defined by an AUDIT score of ≥ 8；&#xD;
&#xD;
          7. Contraindications to RBV or IFN therapy, including hemoglobinopathies (e.g.,&#xD;
             thalassemia major or sickle-cell anemia)；&#xD;
&#xD;
          8. Pregnant or nursing female or male with pregnant female partner；&#xD;
&#xD;
          9. Use of any prohibited medications within 30 days of the Baseline/Day 1 visit；&#xD;
&#xD;
         10. Known hypersensitivity to TG-2349, DAG181, RBV, sulfa drugs, or formulation&#xD;
             excipients；&#xD;
&#xD;
         11. Current or prior history of any of the following: (1) Chronic hepatic disorder not&#xD;
             induced by HCV (including but not limited to Hemochromatosis, Wilson's disease,&#xD;
             alpha-1 antitrypsin deficiency, cholangitis, autoimmune hepatitis, alcoholic liver&#xD;
             disease, drug-induced liver disease. (2) Decompensated liver cirrhosis (Child-Pugh&#xD;
             class B and C). (3) Any dysphagia, malabsorption syndrome, or other gastrointestinal&#xD;
             disturbances affecting drug absorption. (4) Difficulty with blood collection and/or&#xD;
             poor venous access for the purposes of phlebotomy. (5) Central nervous system (CNS)&#xD;
             trauma, seizure disorder, stroke or transient ischemic attack. (6) Solid organ&#xD;
             transplantation. (7) Significant cardiac disease (including but not limited to the&#xD;
             myocardial infarction based on ECG and/or clinical history). (8) Significant pulmonary&#xD;
             disease or porphyria (e.g. lung infiltration or impaired lung function). (9)&#xD;
             Pancreatitis. (10) Autoimmune disease (systemic lupus erythematosus, rheumatoid&#xD;
             arthritis, sarcoidosis, psoriasis). (11) Psychiatric hospitalization, suicide attempt,&#xD;
             and/or a period of disability as a result of their psychiatric illness within the last&#xD;
             5 years. (12) Malignancy within 5 years prior to Screening, with the exception of&#xD;
             specific cancers that are entirely cured by surgical resection (basal cell skin&#xD;
             cancer, etc). Subjects under evaluation for possible malignancy are not eligible. (13)&#xD;
             Serious acute drug allergy (such as anaphylaxis or hepatotoxicity) or serious skin&#xD;
             hypersensitive reaction (such as vesicular rash, Stevens Johnson Syndrome)；&#xD;
&#xD;
         12. As determined by Investigator, a subject that would affect the therapy, evaluation or&#xD;
             compliance with the protocol is not suitable to take part in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lai Wei, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Peoples Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University Peoples Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>10004</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>July 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic hepatics C virus (HCV) genotype 1</keyword>
  <keyword>treatment naïve</keyword>
  <keyword>non-cirrhotic</keyword>
  <keyword>cirrhotic</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>TG-2349</keyword>
  <keyword>DAG181</keyword>
  <keyword>Ribavirin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Yimitasvir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

